<p><strong><em>公司推進其使命，提供下一代糖尿病管理解決方案並擴大全球市場滲透</em></strong></p>
<p><strong><em>下一代柱技術提高了效率，擴大了經常性收入潛力，並增強了 Trinity Biotech 在超過 20 億美元的 HbA1c 市場中的競爭地位</em></strong></p>
<p>都柏林，2025 年 12 月 15 日（全球新聞稿）——Trinity Biotech plc（納斯達克：TRIB）是一家專注於人類診斷和糖尿病管理解決方案的商業階段生物技術公司，包括可穿戴生物傳感器。今天宣佈已在多個國家獲得監管許可，能夠擴大其下一代高容量 HbA1c 柱系統的推廣，該系統現已在包括美國在內的 10 多個國家上市。升級後的系統顯著提高了檢測通量，改善了操作效率，並支持更大的經常性收入機會和利潤擴展，因為公司在不斷增長的全球 HbA1c 市場中鞏固了其領導地位。</p>
<p>全球實驗室 HbA1c 市場目前估計年價值超過 20 億美元，預計到 2030 年將超過 35 億美元。這一 HbA1c 市場的預期增長主要是由於糖尿病的日益普遍。</p>
<p>為 Trinity Biotech 的 Premier Hb9210 分析儀設計的公司專用實驗室 HbA1c 解決方案，升級後的柱系統提供的檢測能力是現有柱系統的四倍，並通過改善穩定性和減少維護需求來最小化儀器停機時間。這些操作上的提升為臨牀實驗室創造了更高效的工作流程，並支持該平台的更廣泛採用。</p>
<p>主要亮點：</p>
<ul>
<li>減少停機時間，提高操作效率，實現更高的通量。</li>
<li>增強的柱穩定性，最小化維護中斷，減輕操作人員的工作負擔。</li>
<li>最新的軟件更新實現了常規任務的額外自動化，提高了生產力和成本節約。</li>
</ul>
<p>Trinity Biotech 的 Premier Hb9210 解決方案繼續被認可為 HbA1c 檢測的黃金標準，已發表的同行評審科學比較研究持續確認該公司 HbA1c 分析儀系統的強大臨牀表現。此外，最近由診斷與實驗室醫學協會發表的一篇文章指出_“儘管如此，BAC（Trinity Biotech）仍然是目前市場上 HbA1c 特異性最高的方法。”_</p>
<p>“在包括美國在內的關鍵市場推出這一先進系統，使 Trinity Biotech 能夠在全球糖尿病護理領域捕捉更多增長機會，” Trinity Biotech 首席執行官兼總裁 John Gillard 表示。“更高的容量、減少的停機時間和自動化的結合為實驗室創造了一個引人注目的價值主張，我們預計在關鍵市場的強勁採用將推動長期股東價值。”</p>
<p>Trinity Biotech 繼續與客户和監管機構密切合作，擴大在其他國家的可用性，強化其對全球市場滲透和糖尿病護理創新的承諾。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本發佈包含根據 1995 年《私人證券訴訟改革法》（“改革法”）的定義構成的 “前瞻性聲明”，包括但不限於與 Trinity Biotech 的現金狀況、財務資源和未來增長潛力、新或計劃產品的市場接受度和滲透率以及未來經常性收入和運營結果相關的聲明。Trinity Biotech 主張根據改革法的前瞻性聲明安全港的保護。這些前瞻性聲明通常以 “可能”、“相信”、“預測”、“期望”、“預期” 或類似含義的詞語為特徵，並不反映歷史事實。本發佈中包含的具體前瞻性聲明可能受到風險和不確定性的影響，包括但不限於我們利用 Waveform 交易和最近收購的能力、我們在納斯達克證券市場的持續上市、我們在未來實現盈利運營的能力、COVID-19 及其變種的傳播影響、美國政府對 Trinity Biotech 生產的 HIV 測試的資金可能暫停和/或中斷、公司分銷商的潛在過剩庫存水平和庫存失衡、與 Trinity Biotech 的設施或製造運營相關的損失或系統故障、匯率波動對國際運營的影響、季度運營結果的波動、對供應商的依賴、Trinity Biotech 產品和服務的市場接受度、產品的持續開發、所需的政府批准、與大規模無缺陷生產和分銷其產品相關的風險、與第三方製造的新儀器引入相關的風險、在人體診斷市場競爭相關的風險、與保護 Trinity Biotech 知識產權或第三方提出的知識產權侵權索賠相關的風險以及與美國經濟狀況相關的風險，以及在 Trinity Biotech 截至 2024 年 12 月 31 日的財政年度的 20-F 表格年報和 Trinity Biotech 不時向美國證券交易委員會提交的其他定期報告中詳細列出的 “風險因素”。前瞻性聲明僅在聲明發布之日有效。Trinity Biotech 不承擔並特別聲明不承擔更新任何前瞻性聲明的義務。</p>
<p><strong>關於 Trinity Biotech</strong></p>
<p>Trinity Biotech 是一家商業階段的生物技術公司，專注於糖尿病管理解決方案和人類診斷，包括可穿戴生物傳感器。該公司開發、收購、製造和銷售診斷系統，包括用於即時護理和臨牀實驗室領域的試劑和儀器，並最近通過收購 Waveform Technologies Inc.的生物傳感器資產進入可穿戴生物傳感器行業，計劃開發一系列生物傳感器設備及相關服務，首個產品為連續血糖監測設備。我們的產品用於檢測傳染病，並量化血清、血漿和全血中的糖化血紅蛋白 A1c 及其他化學參數的水平。Trinity Biotech 在美國直接銷售，並通過全球 75 個國家的國際分銷商和戰略合作伙伴網絡進行銷售。有關更多信息，請訪問公司網站：www.trinitybiotech.com。</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>聯繫方式：</strong></td>
<td><strong>Trinity Biotech plc</strong></td>
<td><strong>RedChip Companies Inc.</strong></td>
</tr>
<tr>
<td></td>
<td>Gary Keating, Ph.D.<br/> (353)-1-2769800</td>
<td>Dave Gentry, CEO <br/> (1)-407-644-4256<br/> (1)-800-RED-CHIP (733-2447)<br/>TRIB@redchip.com</td>
</tr>
</tbody>
</table>
<p>\<em>\</em>\______________________</p>
<p>1 <em>https://www.maximizemarketresearch.com/market-report/global-hba1c-laboratory-tests-market/81466/</em> 2 <em>https://doi.org/10.1080/00365513.2023.2281400</em> <em>和</em> <em>https://doi.org/10.1080/03630269.2025.2524437</em></p>
<p>3 <em>https://myadlm.org/cln/articles/2025/septemberoctober/navigating-hemoglobin-a1c-measurements-for-diabetes-care?utm_campaign=september-cln-monthly-email&amp;utm_medium=email&amp;_hsenc=p2ANqtz--H-b8nqWXfE5QzwxN7g7ng4LhJzv0dDYVj2Cvg-NZlV7uT8_-w9cxM7lAzfzVYdEg1c2QDGQmD_hAXRIAHVcYtRVxNxLe4bPax9TWmCPC1IGjFkjQ&amp;_hsmi=382763562&amp;utm_content=382763562&amp;utm_source=hs_email</em></p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01qSXpOaU0zTXpJeE9EVTJJekl3TVRnNU1UVT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01qSXpOaU0zTXpJeE9EVTJJekl3TVRnNU1UVT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ODJkMjAyYTktM2M0Ny00MDM0LWJmNzgtODUyOWQ2NmU0ODA3LTEwMzA0ODgtMjAyNS0xMi0xNS1lbg==/tiny/Trinity-Biotech-plc.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ODJkMjAyYTktM2M0Ny00MDM0LWJmNzgtODUyOWQ2NmU0ODA3LTEwMzA0ODgtMjAyNS0xMi0xNS1lbg==/tiny/Trinity-Biotech-plc.png"/></p>

Trinity生物科技-A

<p>Trinity 生物科技-A 已獲得其高容量 HbA1c 柱系統的監管批准，擴大在包括美國在內的 10 多個國家的推廣。該系統提高了檢測效率和收入潛力，鞏固了其在超過 20 億美元的 HbA1c 市場中的地位。升級後的系統提供四倍的檢測能力，減少了停機時間，並改善了穩定性，支持更廣泛的採用和長期股東價值</p>

<p><strong><em>Company advances its mission to deliver next-generation diabetes management solutions and expand global market penetration</em></strong></p>
<div class="lb-trans"><p><strong><em>公司推進其使命，提供下一代糖尿病管理解決方案並擴大全球市場滲透</em></strong></p>
</div><p><strong><em>Next-generation column technology enhances efficiency, expands recurring revenue potential, and strengthens Trinity Biotech’s competitive position in the $2B+ HbA1c market</em></strong></p>
<div class="lb-trans"><p><strong><em>下一代柱技術提高了效率，擴大了經常性收入潛力，並增強了 Trinity Biotech 在超過 20 億美元的 HbA1c 市場中的競爭地位</em></strong></p>
</div><p>DUBLIN, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has secured regulatory clearances in multiple countries, enabling the expanded rollout of its next-generation high-capacity HbA1c column system for the Premier Hb9210 analyzer which is now available in more than 10 countries, including the United States. The upgraded system significantly increases testing throughput, improves operational efficiency, and supports greater recurring revenue opportunities and margin expansion as the company strengthens its leadership position in the growing global HbA1c market.</p>
<div class="lb-trans"><p>都柏林，2025 年 12 月 15 日（全球新聞稿）——Trinity Biotech plc（納斯達克：TRIB）是一家專注於人類診斷和糖尿病管理解決方案的商業階段生物技術公司，包括可穿戴生物傳感器。今天宣佈已在多個國家獲得監管許可，能夠擴大其下一代高容量 HbA1c 柱系統的推廣，該系統現已在包括美國在內的 10 多個國家上市。升級後的系統顯著提高了檢測通量，改善了操作效率，並支持更大的經常性收入機會和利潤擴展，因為公司在不斷增長的全球 HbA1c 市場中鞏固了其領導地位。</p>
</div><p>The global laboratory HbA1c market is estimated to be currently worth over $2 billion annually and is expected to grow to exceed $3.5 billion by 2030. This expected rise in the HbA1c market is primarily driven by the increasing prevalence of diabetes1.</p>
<div class="lb-trans"><p>全球實驗室 HbA1c 市場目前估計年價值超過 20 億美元，預計到 2030 年將超過 35 億美元。這一 HbA1c 市場的預期增長主要是由於糖尿病的日益普遍。</p>
</div><p>Designed for Trinity Biotech’s Premier Hb9210 analyzer, the company’s dedicated laboratory HbA1c solution, the upgraded column system delivers up to four times the testing capacity compared to the existing column system and minimizes instrument downtime through improved stability and reduced maintenance requirements. These operational gains create a more efficient workflow for clinical laboratories and support broader adoption of the platform.</p>
<div class="lb-trans"><p>為 Trinity Biotech 的 Premier Hb9210 分析儀設計的公司專用實驗室 HbA1c 解決方案，升級後的柱系統提供的檢測能力是現有柱系統的四倍，並通過改善穩定性和減少維護需求來最小化儀器停機時間。這些操作上的提升為臨牀實驗室創造了更高效的工作流程，並支持該平台的更廣泛採用。</p>
</div><p>Key Highlights:</p>
<div class="lb-trans"><p>主要亮點：</p>
</div><ul>
<li>Reduced downtime and improved operational efficiency, enabling higher throughput.</li>
<li>Increased column stability, minimizing maintenance interruptions and reducing operator workload.</li>
<li>The latest software update delivers additional automation of routine tasks enabling greater productivity and cost savings.</li>
</ul>
<div class="lb-trans"><ul>
<li>減少停機時間，提高操作效率，實現更高的通量。</li>
<li>增強的柱穩定性，最小化維護中斷，減輕操作人員的工作負擔。</li>
<li>最新的軟件更新實現了常規任務的額外自動化，提高了生產力和成本節約。</li>
</ul>
</div><p>Trinity Biotech’s Premier Hb9210 solution continues to be recognized as a gold standard in HbA1c testing, with published peer-reviewed scientific comparative studies continuing to confirm the strong clinical performance of the company’s HbA1c analyzer system2. In addition, a recent article published by the Association for Diagnostics and Laboratory Medicine states <em>“Still, BAC (Trinity Biotech) remains the method with the highest specificity for HbA1c currently on the market.” 3</em></p>
<div class="lb-trans"><p>Trinity Biotech 的 Premier Hb9210 解決方案繼續被認可為 HbA1c 檢測的黃金標準，已發表的同行評審科學比較研究持續確認該公司 HbA1c 分析儀系統的強大臨牀表現。此外，最近由診斷與實驗室醫學協會發表的一篇文章指出_“儘管如此，BAC（Trinity Biotech）仍然是目前市場上 HbA1c 特異性最高的方法。”_</p>
</div><p>“Launching this advanced system in key markets, including the U.S., positions Trinity Biotech to capture further growth opportunities in the global diabetes care segment,” said John Gillard, CEO and President of Trinity Biotech. “The combination of higher capacity, reduced downtime, and automation creates a compelling value proposition for laboratories, and we expect strong adoption in key markets to drive long-term shareholder value.”</p>
<div class="lb-trans"><p>“在包括美國在內的關鍵市場推出這一先進系統，使 Trinity Biotech 能夠在全球糖尿病護理領域捕捉更多增長機會，” Trinity Biotech 首席執行官兼總裁 John Gillard 表示。“更高的容量、減少的停機時間和自動化的結合為實驗室創造了一個引人注目的價值主張，我們預計在關鍵市場的強勁採用將推動長期股東價值。”</p>
</div><p>Trinity Biotech continues to work closely with customers and regulatory authorities to expand availability into additional countries, reinforcing its commitment to global market penetration and innovation in diabetes care.</p>
<div class="lb-trans"><p>Trinity Biotech 繼續與客户和監管機構密切合作，擴大在其他國家的可用性，強化其對全球市場滲透和糖尿病護理創新的承諾。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including but not limited to statements related to Trinity Biotech’s cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. Trinity Biotech claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms “may,” “believes,” “projects,” “expects,” “anticipates,” or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this release may be affected by risks and uncertainties, including, but not limited to, our ability to capitalize on the Waveform transaction and of our recent acquisitions, our continued listing on the Nasdaq Stock Market, our ability to achieve profitable operations in the future, the impact of the spread of COVID-19 and its variants, the possible pause and/or disruption in U.S. Government funding for HIV tests produced by Trinity Biotech, potential excess inventory levels and inventory imbalances at the company’s distributors, losses or system failures with respect to Trinity Biotech’s facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results, dependence on suppliers, the market acceptance of Trinity Biotech’s products and services, the continuing development of its products, required government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Trinity Biotech’s intellectual property or claims of infringement of intellectual property asserted by third parties and risks related to condition of the United States economy and other risks detailed under “Risk Factors” in Trinity Biotech’s annual report on Form 20-F for the fiscal year ended December 31, 2024 and Trinity Biotech’s other periodic reports filed from time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Trinity Biotech does not undertake and specifically disclaims any obligation to update any forward-looking statements.</p>
<div class="lb-trans"><p>本發佈包含根據 1995 年《私人證券訴訟改革法》（“改革法”）的定義構成的 “前瞻性聲明”，包括但不限於與 Trinity Biotech 的現金狀況、財務資源和未來增長潛力、新或計劃產品的市場接受度和滲透率以及未來經常性收入和運營結果相關的聲明。Trinity Biotech 主張根據改革法的前瞻性聲明安全港的保護。這些前瞻性聲明通常以 “可能”、“相信”、“預測”、“期望”、“預期” 或類似含義的詞語為特徵，並不反映歷史事實。本發佈中包含的具體前瞻性聲明可能受到風險和不確定性的影響，包括但不限於我們利用 Waveform 交易和最近收購的能力、我們在納斯達克證券市場的持續上市、我們在未來實現盈利運營的能力、COVID-19 及其變種的傳播影響、美國政府對 Trinity Biotech 生產的 HIV 測試的資金可能暫停和/或中斷、公司分銷商的潛在過剩庫存水平和庫存失衡、與 Trinity Biotech 的設施或製造運營相關的損失或系統故障、匯率波動對國際運營的影響、季度運營結果的波動、對供應商的依賴、Trinity Biotech 產品和服務的市場接受度、產品的持續開發、所需的政府批准、與大規模無缺陷生產和分銷其產品相關的風險、與第三方製造的新儀器引入相關的風險、在人體診斷市場競爭相關的風險、與保護 Trinity Biotech 知識產權或第三方提出的知識產權侵權索賠相關的風險以及與美國經濟狀況相關的風險，以及在 Trinity Biotech 截至 2024 年 12 月 31 日的財政年度的 20-F 表格年報和 Trinity Biotech 不時向美國證券交易委員會提交的其他定期報告中詳細列出的 “風險因素”。前瞻性聲明僅在聲明發布之日有效。Trinity Biotech 不承擔並特別聲明不承擔更新任何前瞻性聲明的義務。</p>
</div><p><strong>About Trinity Biotech</strong></p>
<div class="lb-trans"><p><strong>關於 Trinity Biotech</strong></p>
</div><p>Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Our products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: www.trinitybiotech.com.</p>
<div class="lb-trans"><p>Trinity Biotech 是一家商業階段的生物技術公司，專注於糖尿病管理解決方案和人類診斷，包括可穿戴生物傳感器。該公司開發、收購、製造和銷售診斷系統，包括用於即時護理和臨牀實驗室領域的試劑和儀器，並最近通過收購 Waveform Technologies Inc.的生物傳感器資產進入可穿戴生物傳感器行業，計劃開發一系列生物傳感器設備及相關服務，首個產品為連續血糖監測設備。我們的產品用於檢測傳染病，並量化血清、血漿和全血中的糖化血紅蛋白 A1c 及其他化學參數的水平。Trinity Biotech 在美國直接銷售，並通過全球 75 個國家的國際分銷商和戰略合作伙伴網絡進行銷售。有關更多信息，請訪問公司網站：www.trinitybiotech.com。</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Contact:</strong></td>
<td><strong>Trinity Biotech plc</strong></td>
<td><strong>RedChip Companies Inc.</strong></td>
</tr>
<tr>
<td></td>
<td>Gary Keating, Ph.D.<br/> (353)-1-2769800</td>
<td>Dave Gentry, CEO <br/> (1)-407-644-4256<br/> (1)-800-RED-CHIP (733-2447)<br/>TRIB@redchip.com</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>聯繫方式：</strong></td>
<td><strong>Trinity Biotech plc</strong></td>
<td><strong>RedChip Companies Inc.</strong></td>
</tr>
<tr>
<td></td>
<td>Gary Keating, Ph.D.<br/> (353)-1-2769800</td>
<td>Dave Gentry, CEO <br/> (1)-407-644-4256<br/> (1)-800-RED-CHIP (733-2447)<br/>TRIB@redchip.com</td>
</tr>
</tbody>
</table>
</div><p>\<em>\</em>\______________________</p>
<div class="lb-trans"><p>\<em>\</em>\______________________</p>
</div><p>1 <em>https://www.maximizemarketresearch.com/market-report/global-hba1c-laboratory-tests-market/81466/</em> 2 <em>https://doi.org/10.1080/00365513.2023.2281400</em> <em>and</em> <em>https://doi.org/10.1080/03630269.2025.2524437</em></p>
<div class="lb-trans"><p>1 <em>https://www.maximizemarketresearch.com/market-report/global-hba1c-laboratory-tests-market/81466/</em> 2 <em>https://doi.org/10.1080/00365513.2023.2281400</em> <em>和</em> <em>https://doi.org/10.1080/03630269.2025.2524437</em></p>
</div><p>3 <em>https://myadlm.org/cln/articles/2025/septemberoctober/navigating-hemoglobin-a1c-measurements-for-diabetes-care?utm_campaign=september-cln-monthly-email&amp;utm_medium=email&amp;_hsenc=p2ANqtz--H-b8nqWXfE5QzwxN7g7ng4LhJzv0dDYVj2Cvg-NZlV7uT8_-w9cxM7lAzfzVYdEg1c2QDGQmD_hAXRIAHVcYtRVxNxLe4bPax9TWmCPC1IGjFkjQ&amp;_hsmi=382763562&amp;utm_content=382763562&amp;utm_source=hs_email</em></p>
<div class="lb-trans"><p>3 <em>https://myadlm.org/cln/articles/2025/septemberoctober/navigating-hemoglobin-a1c-measurements-for-diabetes-care?utm_campaign=september-cln-monthly-email&amp;utm_medium=email&amp;_hsenc=p2ANqtz--H-b8nqWXfE5QzwxN7g7ng4LhJzv0dDYVj2Cvg-NZlV7uT8_-w9cxM7lAzfzVYdEg1c2QDGQmD_hAXRIAHVcYtRVxNxLe4bPax9TWmCPC1IGjFkjQ&amp;_hsmi=382763562&amp;utm_content=382763562&amp;utm_source=hs_email</em></p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01qSXpOaU0zTXpJeE9EVTJJekl3TVRnNU1UVT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYwMjIzNiM3MzIxODU2IzIwMTg5MTU="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ODJkMjAyYTktM2M0Ny00MDM0LWJmNzgtODUyOWQ2NmU0ODA3LTEwMzA0ODgtMjAyNS0xMi0xNS1lbg==/tiny/Trinity-Biotech-plc.png" alt="" original-src="https://ml.globenewswire.com/media/ODJkMjAyYTktM2M0Ny00MDM0LWJmNzgtODUyOWQ2NmU0ODA3LTEwMzA0ODgtMjAyNS0xMi0xNS1lbg==/tiny/Trinity-Biotech-plc.png"/></p>

Trinity Biotech Expands Global Rollout of High-Capacity Column System for FDA-Cleared HbA1c Testing Solution After Securing Regulatory Clearances | TRIB Stock News

Trinity 生物科技-A 在獲得監管批准後，擴大了其 FDA 批准的 HbA1c 檢測解決方案的高容量柱系統的全球推廣 | TRIB 股票新聞